| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Lannett has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| LCI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| Lannett Co Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for LCI | 13 |
$25 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) | 101 |
$169 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) | 103 |
$169 |
0.29% Nasdaq 
0.02 (0.32%) 
Research Reports
